SAB Biotherapeutics Inc. (SABS)
3.48
-0.07 (-1.97%)
At close: Jan 15, 2025, 3:59 PM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Net Income | -42.19M | -17.14M | -17.14M | 20.12M | -8.99M |
| Depreciation & Amortization | 3.75M | 1.65M | 1.65M | 548.18K | 323.41K |
| Stock-Based Compensation | 2.42M | 2.67M | 2.31M | 1.30M | 371.39K |
| Other Working Capital | -528.64K | 3.83M | 3.83M | 100.00K | 84.50K |
| Other Non-Cash Items | 8.58M | 3.48M | 3.48M | -2 | 1.00 |
| Deferred Income Tax | n/a | n/a | n/a | -2.25K | 421.00 |
| Change in Working Capital | 2.33M | 13.45M | 13.45M | -11.95M | -923.37K |
| Operating Cash Flow | -25.12M | 3.76M | 3.76M | 10.00M | -9.21M |
| Capital Expenditures | -197.15K | -10.94M | -10.94M | -12.73M | -608.75K |
| Acquisitions | n/a | 76.39K | n/a | 9.00K | n/a |
| Purchase of Investments | n/a | n/a | n/a | n/a | n/a |
| Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | 44.45K | -76.39K | -10.94M | n/a | n/a |
| Investing Cash Flow | -152.70K | -10.94M | -10.94M | -12.72M | -608.75K |
| Debt Repayment | -390.44K | -1.19M | 1.54M | -917.88K | n/a |
| Common Stock Repurchased | n/a | -5.52M | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 67.16M | 76.97K | 32.58M | 9.90M | n/a |
| Financial Cash Flow | 66.77M | 34.12M | 34.12M | 8.98M | 3.68M |
| Net Cash Flow | 41.52M | 26.93M | 26.93M | 6.26M | -6.14M |
| Free Cash Flow | -25.32M | -7.19M | -7.19M | -2.73M | -9.82M |